MediciNova, Inc. (MNOV)
 NASDAQ: MNOV · Real-Time Price · USD
 1.265
 +0.075 (6.30%)
  Oct 31, 2025, 10:31 AM EDT - Market open
MediciNova Revenue
MediciNova had revenue of $134.60K in the quarter ending June 30, 2025. This brings the company's revenue in the last twelve months to $134.60K, down -86.54% year-over-year.
Revenue (ttm) 
 $134.60K
Revenue Growth 
 -86.54%
P/S Ratio 
 433.62
Revenue / Employee 
 $10,354
Employees 
 13
Market Cap 
62.04M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth | 
|---|---|---|---|
| Dec 31, 2024 | - | - | - | 
| Dec 31, 2023 | 1.00M | - | - | 
| Dec 31, 2022 | - | - | - | 
| Dec 31, 2021 | 4.04M | - | - | 
| Dec 31, 2020 | - | - | - | 
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue | 
|---|---|
| UnitedHealth Group | 435.16B | 
| Johnson & Johnson | 92.15B | 
| Merck & Co. | 64.24B | 
| Eli Lilly and Company | 59.42B | 
| AbbVie | 58.33B | 
| AstraZeneca | 56.50B | 
| Novartis AG | 56.37B | 
| Novo Nordisk | 49.11B | 
MNOV News
- 15 hours ago - MediciNova Compounds Demonstrate Novel Therapeutic Approach for Atherosclerosis in Peer-Reviewed Publication - GlobeNewsWire
- 25 days ago - MediciNova to Present at the LD Micro Main Event XIX Investor Conference - GlobeNewsWire
- 7 weeks ago - MediciNova Provides Shareholder Update on Key Developments - GlobeNewsWire
- 2 months ago - MediciNova to Present at the H.C. Wainwright 27th Annual Global Investment Conference - GlobeNewsWire
- 2 months ago - MediciNova Achieves Enrollment in COMBAT-ALS Clinical Trial - GlobeNewsWire
- 3 months ago - MediciNova Announces Signing of a Standby Equity Purchase Agreement for up to $30 Million - GlobeNewsWire
- 3 months ago - MediciNova Provides Enrollment Update for Ongoing ALS and Hypertriglyceridemia Clinical Trials - GlobeNewsWire
- 7 months ago - MediciNova To Participate in D. Boral's Capital Global Conference on May 14, 2025 - GlobeNewsWire